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Analyses of p53 antibodies in sera of patients with lung carcinoma define
immunodominant regions in the p53 protein
B. Schlichtholzl*, J. Tredaniel2, R. Lubin', G. Zalcman2t, A. Hirsch2 & T. Soussil
'Unite 301 INSERM, Institut de Genetique Moleculaire, 75010 Paris, France; 2Service de Pneumologie, H6pital St Louis, 75010
Paris, France.
Summary Antibodies specific for human p53 were analysed in sera of lung cancer patients. We detected p53
antibodies in the sera of 24% (10/42) of patients with lung carcinoma. The distribution was as follows: 4/9
small-cell lung carcinomas (SCLCs), 2/18 squamous cell lung carcinomas (SCCs), 2/10 adenocarcinomas
(ADCs) and 2/5 large-cell lung carcinomas (LCCs). p53 antibodies were always present at the time of
diagnosis and did not appear during progression of the disease. Using an original peptide-mapping procedure,
we precisely localised the p53 epitopes recognised by p53 antibodies. Immunodominant epitopes reacting with
antibodies were localised in the amino and carboxy termini of the protein, similar to those found in breast
carcinoma patients or in animals immunised with p53. In light of these data, we suggest that p53 antibodies
occur via a self-immunisation process that is the consequence of p53 accumulation in tumour cells. p53
antibodies were also detected in two patients without detected malignant disease. One of these patients died 6
months later of lung carcinoma, suggesting that p53 antibodies may be a precocious marker of p53
alteration.
The p53 gene has been found to be mutated in various
cancers, including colon and breast tumours, and also
leukaemia, osteosarcoma, ovarian cancer, stomach cancer
and brain tumours (Hollstein et al., 1991; Caron de
Fromentel & Soussi, 1992). Recently, germline mutations
were shown to be the basis for the Li-Fraumeni inherited
cancer family syndrome (Malkin et al., 1990; Srivastava et
al., 1990). p53 alterations appear to be present in 40-45% of
the ten tumours most frequently found worldwide. These
mutations are commonly point missense mutations clustered
in four of the five highly conserved domains (HCDs) of the
p53 protein (Soussi et al., 1990).
A decade ago, Benchimol et al. (1982) used a radio-
immunological assay to show that p53 protein was
specifically overexpressed in transformed cells, but was
undetectable in normal cells. Numerous studies have
confirmed these observations and shown that p53 protein
accumulation is a consequence of its stabilisation. We now
know that stabilisation is usually due to a point mutation
that modifies the conformation and stability of the protein.
This observation has encouraged intensive study of the ex-
pression of p53 protein by immunohistochemistry on a large
panel of tumours, since there seems to be a good correlation
between molecular analysis and immunohistochemistry
(Bartek et al., 1991; Hall et al., 1991).
Another approach to analysis of p53 alterations in human
cancers consists of serological dosage of p53 antibodies
found in sera of patients with various types of cancers. This
work was based on results of Crawford et al. (1982), who
detected p53 antibodies in sera of patients with breast car-
cinoma. Caron de Fromental et al. (1987) later found that
such antibodies were present in sera of children with a wide
variety of cancers. The average frequency was 12%, but this
figure rose to 20% for Burkitt's lymphoma. More recently, it
has been demonstrated that the presence of p53 antibodies is
associated with p53 mutations (Davidoff et al., 1992; Winter
et al., 1992). While it is not clear whether the site of mutation
on the protein contributes to the antibody response, the
occurrence is related to those mutations that result in p53
overexpression (Winter et al., 1992). In addition, such
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antibodies are not specific for a particular p53 mutant, and
recognise both wild-type and various p53 mutants in a
similar manner (Schlichtholz et al., 1992; Winter et al., 1992;
Labrecque et al., 1993). In breast carcinoma, it was shown
that these antibodies are directed toward immunodominant
epitopes localised in the amino terminus of p53 protein
(Schlichtholz et al., 1992). Finally, a close correlation was
observed between the presence of such antibodies and other
poor prognosis factors, such as high histological grade and
the absence of hormone receptors (Schlichtholz et al.,
1992).
Lung cancer is the leading cause of cancer death in western
countries. Small-cell lung carcinoma (SCLC) accounts for
approximately 20% of lung cancers, while the remaining
80% fall into the broad category of non-small-cell car-
cinomas (NSCLCs), which include squamous cell carcinomas,
adenocarcinomas and large-cell carcinomas. Among the mul-
tiple genetic changes which have been described in lung
cancer, p53 alteration is by far the most common and is
found in about 75% of SCLCs and 45-55% of NSCLCs, as
detected by DNA sequencing of the p53 gene from tumour
cells (Takahashi et al., 1989, 1991; Chiba et al., 1990;
D'Amico et al., 1992; Kishimoto et al., 1992; Mitsudomi et
al., 1992; Suzuki et al., 1992). The presence ofp53 mutations,
presumably as the result of exposure to environmental car-
cinogens (tobacco smoke), has been reported in premalignant
bronchial lesions, e.g. mild or severe epithelial bronchial
dysplasia (Sundaresan et al., 1992). Because these mutations
may induce the production of circulating antibodies, a simple
test based on the detection of p53 antibodies in sera of
patients with lung tumours and those at high risk for lung
carcinoma is of great interest.
In order to document this approach, we performed
serological p53 antibody studies on patients recruited from
the Respiratory Medicine Department of the H6pital Saint-
Louis, Paris, France. First, we sought to assess the presence
of serum antibodies to p53 in patients with lung cancer and
to compare the rate of formation of p53 antibodies in such
patients with that of p53 antibodies in patients referred to
the same department for non-malignant diseases. Second, we
undertook a precise characterisation of these antibodies by
using an original peptide ELISA procedure.
Materials and methods
Sera
Sera were collected from May 1992 to October 1992, on the
occasion of routine blood analysis; 7 ml of whole blood was
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centrifuged at 3,000 r.p.m. for 15 min and supernatant was
stored at - 80°C until use.
All analyses were done in duplicate. Patients' and control
subjects' sera were analysed in random order and with the
observer blind to the patient/control status.
p53fusion protein expressed in Escherichia coli
The pLip4 vector (Gillet et al., 1992; Schlichtholz et al.,
1992) used for the production of hybrid proteins has been
described previously. Well-defined regions of human p53
were amplified by polymerase chain reaction (PCR) and then
subcloned in the pLIP4 vector in fusion with the phoA gene
(Schlichtholz et al., 1992). p53 was divided into six well-
defined fragments. Fragments 2 (residues 108-162), 3
(residues 158-219), 4 (residues 215-267) and 5 (residues
263-310) included HCD II-V, respectively, and corres-
ponded to the hotspot for mutations in human cancer.
Fragments 1 (residues 1-112) and 6 (residues 306-393) cor-
responded to the amino and carboxy termini of the protein
and were usually devoid of mutations (Caron de Fromentel
& Soussi, 1992). The antigenicity of the expressed hybrid
protein was assessed by its reactivity with various MAbs with
a known specificity (Schlichtholz et al., 1992).
Immunoblotting, immunoprecipitation and ELISA
The procedure for testing human sera by immunoblot has
already been described (Schlichtholz et al., 1992). The fusion
proteins encompassing p53 fragments were expressed in E.
coli (see above), whereas full-length human p53 was exp-
ressed in insect cells infected with a recombinant baculovirus.
For immunoprecipitation, full-length wild-type p53 was
obtained by in vitro transcription/translation. For each
immunoprecipitation, 10,000 c.p.m. of labelled protein was
used as described by Soussi et al. (1989). The ELISA proce-
dure used to assess p53 antibodies will be described elsewhere
(R. Lubin and T. Soussi, manuscript in preparation). Briefly,
we have devised a highly specific ELISA by testing all the
sera with two antigen preparations. The first preparation
contains the relevant antigen, i.e. p53, whereas in the second
preparation this antigen was omitted. All the results have
been expressed as the ratio between the value of the wells
with p53 and the corresponding wells without p53. As
preliminary experiments in our laboratory have shown that
ELISA dosage with human sera can lead to a variable back-
ground depending upon the sera, we devised this procedure
to include an internal control. Studies on sera from healthy
blood donors (200) and patients with various carcinomas
(more than 1,000) indicate that a ratio higher than 2 confirms
the presence of p53 antibodies.
PEPSCAN analysis
Immunoscreening was performed using the procedures des-
cribed by Geysen et al. (1984). Peptides (a total of 77)
consisting of overlapping 15-mers spanning the entire human
p53 were produced by Cambridge Research Biochemicals
(UK). Each peptide overlapped its neighbour by ten amino
acids and was biotinylated at its amino terminus.
Plates were coated with 5 gtgml- streptavidin diluted in
water. For each well, 100 tl of solution was used. Plates were
left at 37°C until the solution evaporated to dryness. Dried
plates were either used immediately or stored at 4°C in a
sealed bag.
Plates were washed six times in phosphate-buffered saline
(PBS) containing 0.05% (v/v) Tween 20 (PBS-T) and subse-
quently blocked with PBS containing 5% milk for 1 h at
37°C; 50jil ofeach biotinylated peptide (5 nggil-l) was added
to individual wells of the plate and incubated for 1 h at room
temperature on a rocking table and then washed five times
before addition of sera at a 1:50 dilution. Plates were washed
five times before development of the immune complex with
peroxidase-labelled antibodies.
Results
Detection ofp53 antibodies in sera
All sera were tested for p53 antibodies by immunoprecipita-
tion and ELISA. Immunoprecipitation was performed on
labelled p53 protein obtained by an in vitro transcription/
translation assay. For the ELISA, we used wild-type human
p53 produced in insect cells infected with a recombinant
baculovirus. Since initial experiments showed that different
human sera can lead to various background levels with sharp
variations, we devised an ELISA procedure in which each
serum was tested on both human p53 and irrelevant antigen
(R. Lubin & T. Soussi manuscript in preparation). In this
assay, results are expressed as the ratio of the values obtained
with the p53 protein and the irrelevant antigen. A positive
serum from a patient with a breast carcinoma was taken as
the lower limit for the positive value. This serum was shown
to have p53 antibodies by both immunoblotting and
immunoprecipitation (Schlichtholz et al., 1992). Furthermore,
a peptide-scanning experiment showed that antibodies found
in this serum corresponded to p53-specific antibodies directed
to the immunodominant epitope of p53 (data not shown).
p53 antibodies in lung cancerpatients
From May 1992 to October 1992, 42 patients with lung
carcinomas were referred to our institution: nine had SCLCs,
18 had SCCs, ten had ADCs and five had (LCCs). Among
these patients, 24% (10/42), exhibited serum antibodies to
p53 (Table I and Figure 1). Of these, 4/9 were SCLCs, 2/18
SCCs, 2/10 ADCs and 2/5 LCCs. However, because of the
small number of patients with SCLCs, further studies will be
necessary to assess the precise rate ofeach subtype presenting
antibodies to p53.
Most of these sera reacted with human p53 irrespective of
the methods used (immunoprecipitation, immunoblot or
ELISA), but three sera (patients LC32, LC149 and LC193)
were shown to be either very low or negative when tested by
ELISA, whereas they were fairly effective by immuno-
precipitation (see below). Serum from patient LC6 was
positive by immunoprecipitation, but negative in both
Western blot and ELISA. Therefore it was considered as
negative.
Five lung cancer patients with p53 antibodies were tested
on several occasions during their treatment (Table I; see also
Figure 4). They maintained a high level of p53 antibodies in
their sera. Although indicative, these data do not enable a
correlation between progression of disease and the level of
p53 antibodies because of the small number of patient sam-
ples. Five lung cancer patients without p53 antibodies were
also tested on several occasions over a period of 1 year. In
no case could we find p53 antibodies during progression of
the disease. It must be noted that all primary samples were
taken at the time of patient presentation prior to any treat-
ment. Taken together, these data suggest that the humoral
response of patients to p53 could precede detection of the
tumour.
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Figure 1 Proportion of patients with p53 antibodies in their
sera. Three patients had antibody level outside of the scale used
for the graph. BC20 corresponds to p53-positive sera used as
controls in our ELISA procedure. Patients PT37 and PT90 are
included in this figure as open circles.
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Table I Analysis of p53 antibodies in the sera of lung
LC3
LC6
LC19-74b
LC22
LC40
LC47
LC61-178-195b
LC78
LC109
LC128
LC147
LC151
LC154
LC156-164b
LC162-179-192b
LC167
LC169
LCI80
LC32
LC93
LC136-150-187b
LC158
LC177
LC16
LC57
LC66
LC103
LC132
LC148-198b
LC157-183-l1lb
LC189
LC186
LC188
LC18-73-133b
LC31
LC46
LC84
LC131-149-172-197b
LC135
LC144
LC160-171-184b
LC193
PT37-170-196b
PT43
PT90
Cancer
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
LCC
LCC
LCC
LCC
LCC
ADC
ADC
ADC
ADC
ADC
ADC
ADC
ADC
ADC
ADC
SCLC
SCLC
SCLC
SCLC
SCLC
SCLC
SCLC
SCLC
SCLC
'P
+
ELISA
+
PeptideSa
3-4-49
9-72-73
59-62-71
9-10-18
4-5-13
6-9-10
3-4-25
4-9-10
9-21-70
16-67-68
4-9-25
8-69-70
10-41-42
cancer patients
Sex/age
M/53
M/74
M/54
M/68
M/60
M/69
F/45
M/78
M/61
M/71
M/80
M/61
M/59
M/60
F/66
F/57
M/50
M/66
F/70
M/84
M/57
M/49
F/58
F/64
F/56
M/67
F/66
F/71
F/65
F/43
M/54
M/69
F/48
M/67
F/68
M/56
F/48
F/69
M/44
M/51
M/43
M/76
M/64
F/71
M/43
Pqt
30
20
40
100
75
60
40
120
80
20
60
45
70
20
50
0
60
45
25
120
40
25
120
0
20
100
0
40
148
0
NA
50
0
100
20
70
40
30
NA
70
30
30
60
45
30
aThe three strongest peptides recognised by the sera. bSamples from the same patient over a 1 year
period. IP, immunoprecipitation; Pqt, mean smoking (pack-years); ND, not done: NA, not
available.
Characterisation ofthe epitope recognised by the p53
antibodies
In another report, we showed that p53 antibodies found in
the sera of breast cancer patients recognised immuno-
dominant epitopes localised predominantly in the amino
and, to a lesser extent, in the carboxy terminus of the p53
protein (Schlichtholz et al., 1992). Using the Western blot
procedure described in Materials and methods, we tested the
behaviour of sera from patients with lung carcinoma. Figure
2 clearly shows that the immune response in these patients
was also directed mainly towards epitopes located in
fragments 1 and 6 of p53. Sera of some patients recognised
only fragment 1, but none recognised only fragment 6,
indicating that the primary response was directed mainly
towards fragment 1. These results are in complete agreement
with those obtained for breast carcinoma, suggesting that p53
antibodies are produced via a similar mechanism in both
types of cancer.
In order to gain further insight into the epitopes recog-
nised by the antibodies, we used a series of 77 biotinylated
peptides (15 residues each) encompassing the whole p53 pro-
tein. Each peptide had an overlap of ten amino acids with its
neighbour (see Materials and methods). Using a 'PEPSCAN'
procedure, all positive sera were tested for their precise
epitope locations. This approach confirmed the results
Fusion protein Fusion protein
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Figure 2 Immunoblot characterisation ofp53 antibodies. Protein
extracts used for analysis included: p53, intact human p53 pro-
duced in insect cells; Ph, E. coli alkaline phosphatase; 1-6,
protein extracts from E. coli that express the p53 fusion protein.
The sera used for the immunoblot were: 1, sera from patient 132;
2, sera from patient 37; 3, sera from patient 84; 4, control
experiment with an anti-alkaline phosphatase antibody.812 B. SCHLICHTHOLZ et al.
obtained in the immunoblotting experiment. Furthermore,
our data demonstrated that only a subset of amino sequences
was recognised by the antibodies. Two immunodominant
regions were localised in the amino terminus of p53 (Figures
3-5). The localisation of the epitope in the carboxy terminus
is less clear, as it may vary from one serum to another.
Generally, however, it includes the 30 carboxyl residues of
the protein.
Three sera recognised epitopes localised mainly in the car-
boxy terminus of p53 (patients LC32, LC149 and LC193); it
is interesting to note that the positive reactivity of these p53
antibodies in these sera was very difficult to assess by ELISA
test, whereas they were classified as positive by
immunoprecipitation. Using various coating procedures, we
found that the carboxy terminus of human p53 is very sen-
sitive to denaturation. This feature can affect recognition by
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the antibodies even with sera having a high titre of p53
antibodies (for example LC193, data not shown). This obser-
vation appears to be specific for a given serum as multiple
samples from one patient (LC149) were tested over a period
of more than 1 year without any variation in its
behaviour.
For five patients, we were able to obtain sera during or
after treatment. Peptide-scanning experiments showed that
the epitopes recognised by these sera did not change, sugges-
ting that p53 presentation is similar during the course of the
disease (Figure 4) and does not change.
p53 antibodies in patients with non-malignant disorders
Using the ELISA and immunoprecipitation approaches des-
cribed above, we also evaluated patients, referred for having
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Figure 3 Mapping of antigenic sites in the human p53 protein by PEPSCAN analysis. Control sera 1 and 2 correspond to sera
from healthy donors.
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Figure 4 Evolution of immunogenicity of human p53 during the course of disease using PEPSCAN analysis.
non-malignant disorders, for the presence of antibodies to
p53 during the same period: 14 patients suffered from
asthma, 11 presented with bacteriologically documented pul-
monary tuberculosis, 12 were treated for infectious
pneumonia and 18 fulfilled the criteria for the diagnosis of
chronical obstructive pulmonary disease (COPD). One
patient was explored for sleep apnoea syndrome, while
another presented with chronic cough attributed to
oesophageal reflux and a third patient had a benign tumour
of the trachea (tracheal chondroma).
Among these patients, two (PT90 and PT37) were found to
have p53 serum antibodies by ELISA and the
immunoprecipitation test, whereas one (PT43) was positive
by immunoprecipitation and negative by the ELISA and
Western blot procedure.
Patient PT43 had sleep apnoea syndrome and was a heavy
smoker. However, she had no clinical signs of cancer in any
organ. The thoracic radiograph was normal and broncho-
scopic examination was not performed. This patient is alive
with no patent cancer 1 year after she was referred to our
clinical department. Peptide analysis of her serum showed
that the recognised peptides were rather unusual and did not
correspond to any dominant epitope found for lung car-
cinoma (Figure 5) or for other carcinomas (unpublished
results). Thus far, we have not observed any serum from
cancer patients recognising peptide 8. We tentatively con-
clude that positive results obtained with this serum by
immunoprecipitation reflect cross-reactivity with another
antigen.
Patient PT90 was a 35 year-pack current smoker and had a
long history of chronic cough. Chest radiograph, pulmonary
function and brochoscopic procedure were shown to be nor-
mal. When referred .to us 6 months later, for persistence of
cough, the chest radiograph and fibreoptic examination with
systematic bronchial biopsies were still normal. However,
oesophageal 24 h pH monitoring showed gastro-oesophageal
reflux, and anti-reflux therapy was initiated. Four months
later, the patient was hospitalised for symptoms of acute
cardiorespiratory distress, leading to the discovery of neo-
plastic pericarditis. Chest radiography showed a round
opacity of the left superior lobe of the lung with endoscopic
tumoral obstruction. Optical fibre bronchoscopic biopsy
showed squamous carcinoma. The patient refused
chemotherapy and was lost for follow-up. Serum from this
patient showed a strong signal by immunoprecipitation and
by ELISA. Furthermore, peptide analysis showed a profile
typical of the presence of p53 antibodies, with a strong
reaction with peptides 5, 9 and 10 (Figure 5). Thus, while this
patient with p53 serum antibodies could not be considered as
a patient 'with non-malignant disease', it is of interest that
p53 antibodies were detected 4 months before any clinical
evidence of lung cancer.
Patient PT37 was referred to the respiratory department
for inspiratory dyspnoea, leading to the discovery of an
obstructive tracheal tumour. This tumour was shown to be a
benign tracheal chondroma, and total resection of the
tumour was achieved by surgery. No recurrence was reported
more than 1 year later. This tumour was shown to be
negative by immunohistochemical analysis with p53
antibodies (data not shown). The serum of patient PT37 gave
a strong signal by immunoprecipitation and by ELISA. Fur-
thermore, peptide analysis showed a profile typical of the
presence of p53 antibodies, with a strong reaction with pep-
tides 4, 9 and 10. Multiple samples from this patient showed
that p53 antibodies were still present after more than 1 year.
Interestingly, this patient exhibited a benign IgG monoclonal
lambda-type immunoglobulin (Ig) with normal calcaemia,
normal haemoglobin, normal myelogram, no decrease in
other immunoglobulins and no lytic bone lesion. Studies are
in progress to determine the immunospecificity of this
monoclonal Ig in order to determine whether it is directed to
p53.
Discussion
In this report, we show that 10/42 patients with lung car-
cinomas referred to the respiratory department over a 6
month period had circulating p53 antibodies. The
predominance of squamous cell carcinomas (19/42) among
these patients was in accordance with European
epidemiological data, whereas North American authors have
reported higher rates of adenocarcinomas (Bains, 1991).
Among all the patients exhibiting antibodies to p53, there
were 4/9 small-cell lung carcinomas, 2/18 squamous cell car-
cinomas, 2/10 adenocarcinomas and 2/5 large-cell car-
cinomas. These results are likely to reflect the frequent p53
gene alterations in lung carcinoma subtypes, as reported in
the literature (Takahashi et al., 1989, 1991; Chiba et al.,
1990; Sameshima et al., 1992; Suzuki et al., 1992). However,
the small number of patients, especially with SCLC, will
necessitate further studies to delineate the rate of each sub-
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Figure 5 Mapping of antigenic sites in the human p53 protein by PEPSCAN analysis.
type presenting antibodies to p53 (currently in progress). In
any case, our results confirm that some patients with lung
carcinomas have circulating antibodies that specifically recog-
nise the p53 protein, as tested by different procedures. This is
in agreement with a recent study by Winter et al. (1992), who
showed that 4 out of 40 sera from patients with SCLCs were
positive. The higher frequency of positive sera described here
(4/9 for SCLCs and 10/42 for overall lung carcinomas) is
readily explained by the procedure used for detection of p53
antibodies. Western blot used in their study was far less
sensitive than the ELISA or immunoprecipitation assay des-
cribed here. Nevertheless, we cannot exclude the possibility
of other variations due to sampling or bias in patient selec-
tion.
To characterise the specificity of antibodies, two app-
roaches were attempted. The first one consisted of immuno-
blot with truncated p53 protein. This gave results very
similar to those obtained with sera from patients with breast
carcinomas, e.g. preferential recognition of the amino and
carboxy termini of the protein (Schlichtholz et al., 1992). The
second, based on an ELISA-peptide procedure, enabled map-
ping of these immunodominant epitopes. As was the case for
the immunoblotting experiment, the antibodies reacted with
peptides representing the amino and carboxy termini of the
p53 protein. Two regions in the amino terminus were always
the target for these antibodies. They included peptide 3-5
(EPPLSQETFSDLWKLLPENN4VLSPL) and peptide 9-10
(DDLMLSPDDIEQWFTEDPGP). In the carboxy terminus,
the region recognised by antibodies of the sera was more
heterogeneous and ranged from peptide 70 to 77. Analysis of
monoclonal antibodies produced against human p53 demon-
strated a strong bias in the epitope recognised by these
monoclonal antibodies. Most of them recognised epitopes
localised in the amino terminus of p53 (Wade-Evans & Jen-
kins, 1985; Vojtesek et al., 1992; Bartek et al., 1993; Legros
et al., 1993). Furthermore, we showed that p53 antibodies in
sera of animals hyperimmunised with human p53 recognised
epitopes similar to those identified in a previous work
(Schlichtholz et al., 1992; Y. Legros & T. Soussi, submitted
for publication). Finally, Winter et al. (1992) found a strong
correlation between the level of p53 in cells and the presence
of p53 antibodies, suggesting that p53 stabilisation and its
resulting overexpression are an essential prerequisite for the
presence of p53 antibodies. Taken together, all these data
suggest (i) that p53 antibodies are produced through a self-
immunisation phenomenon which is the consequence of p53
protein overexpression and (ii) that p53 antibodies found in
breast and lung carcinomas arise via a similar mechanism.
It is interesting to note that these amino and carboxy
regions are totally devoid of any mutations in human
cancers, indicating that the antibodies are directed towards
p53 domains that are not altered by mutations. Indeed,
several studies have shown that patients' sera recognised both
wild-type and p53 mutants in a similar manner (Schlichtholz
et al., 1992; Winter et al., 1992; Labrecque et al., 1993). This
observation also suggests that the localisation of the muta-
tion in the p53 protein is not a major determinant in the
immune response of these patients.
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Therapeutic results in lung carcinomas are often disappoin-
ting; the case fatality rate is higher than 90%, and despite
multimodality therapeutic regimens and the introduction of
new drugs little progress has been made in the last decade
(Schaake-Koning et al., 1992; Ihde, 1993). Because screening
by chest radiography or cytology has not resulted in a reduc-
tion in lung cancer mortality, current research is directed
towards the identification of earlier markers of malignancy.
There is now accumulating evidence to suggest that multiple
genetic events occur in the development of lung cancer,
including point mutations in the ras gene, overexpression in
the HER2-NEU gene, loss of heterozygosity of chromosome
3p and deletions or mutations in tumour-suppressor genes
such as Rb and p53. In fact, a p53 alteration has been found
in lung dysplasia, known to occur 3-15 years before the
development of a tumour (Sundaresan et al., 1992).
It is noteworthy that two patients with no history of
tumours at the time of presentation had p53 antibodies in
their sera, suggesting that these antibodies may be present
very early. It is certain that these antibodies were directed to
p53: (i) they recognised p53 irrespective of the methodology
used (ELISA, immunoprecipitation or Western blot); (ii)
epitope analysis indicated that these sera recognised the same
immunodominant peptide as those found in breast cancer
patients' sera. Furthermore, the dramatic disease progression
in patient PT90, with rapid spread of lung cancer, strongly
suggested that these antibodies were indeed directed toward
the p53 protein overexpressed in tumoral tissue, which could
not be detected using conventional diagnostic procedures.
These data support the notion that the occurrence of p53
antibodies may be related to the presence of occult cancers or
premalignant lesions which were not detected by current
procedures. Thus, the presence of p53 antibodies may con-
stitute an earlier marker of lung tumours. This hypothesis is
reinforced by the observation that (i) p53 antibodies are
always present at the time of diagnosis and (ii) p53
antibodies do not appear during tumour development.
In this study, we have shown that p53 antibodies did not
vary significantly during the course of disease in the four
patients tested on several occasions during treatment and
who maintained a high level of p53 antibodies in their sera.
This result was not unexpected, since none of these patients
experienced complete response to chemotherapy. Moreover,
two of them rapidly progressed to cerebral metastases, while
the two remaining patients were radiologically stabilised for
only 4 and 5 months. From this point of view, small-cell
cancers could represent a situation of interest. In this histo-
logical subtype of lung cancer, a complete response can be
obtained in more than 50% of patients with limited disease
using combination therapeutic regimens that associate
polychemotherapy and radiotherapy (Ihde, 1993). It would
be advantageous to determine whether, in patients who show
complete remission, circulating antibodies to p53 disappear
or whether the antibody level increases again when the
tumour recurs (generally between 12 and 18 months after
diagnosis). p53 antibodies would thus represent a useful tool
for early detection of recurrence. Such a prospective mul-
ticentre study is in progress on a much larger number of
patients with SCLC.
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